Title: Inflammatory Biomarker Correlations and Prognosis in High-risk Gastrointestinal
Stromal Tumor Patients: A Multicenter Retrospective Analysis
Version: 1 Date: 25 Sep 2024
Reviewer:  Tsunehiko Maruyama
Reviewer's report:
This article reports on the clinical usefulness of NLR in predicting the prognosis of patients with
high-risk GIST. I have a few questions.
1. Is it acceptable to use the median value as the cut-off value for NLR, PLR, SII and PNI? In
many other reports, analyses are carried out using various cut-off values. If you change the cut-
off value, is there significant difference in the multivariate analysis?
2. There are not many cases of imatinib being administered to high-risk patients, but is there a
problem with the level of medical care?
3. What kind of treatment strategy would you use for a high-risk GIST patient who has been
judged to have a poor prognosis by NLR?
Title: Inflammatory Biomarker Correlations and Prognosis in High-risk Gastrointestinal
Stromal Tumor Patients: A Multicenter Retrospective Analysis
Version: 1 Date: 25 Sep 2024
Reviewer:  Tsunehiko Maruyama
Reviewer's report:
This article reports on the clinical usefulness of NLR in predicting the prognosis of patients with
high-risk GIST. I have a few questions.
1. Is it acceptable to use the median value as the cut-off value for NLR, PLR, SII and PNI? In
many other reports, analyses are carried out using various cut-off values. If you change the cut-
off value, is there significant difference in the multivariate analysis?
2. There are not many cases of imatinib being administered to high-risk patients, but is there a
problem with the level of medical care?
3. What kind of treatment strategy would you use for a high-risk GIST patient who has been
judged to have a poor prognosis by NLR?
Please review this paper.
user
Title: Inflammatory Biomarker Correlations and Prognosis in High-risk Gastrointestinal
Stromal Tumor Patients: A Multicenter Retrospective Analysis
Version: 1 Date: 25 Sep 2024
Reviewer:  Tsunehiko Maruyama
Reviewer's report:
This article reports on the clinical usefulness of NLR in predicting the prognosis of patients with
high-risk GIST. I have a few questions.
1. Is it acceptable to use the median value as the cut-off value for NLR, PLR, SII and PNI? In
many other reports, analyses are carried out using various cut-off values. If you change the cut-
off value, is there significant difference in the multivariate analysis?
2. There are not many cases of imatinib being administered to high-risk patients, but is there a
problem with the level of medical care?
3. What kind of treatment strategy would you use for a high-risk GIST patient who has been
judged to have a poor prognosis by NLR?
assistant